Top

Published in:

01-01-2015 | Letter to the Editors

Intense immunosuppression for the treatment of an immune reconstitution inflammatory syndrome-like exacerbation after natalizumab withdrawal: a case report

Authors: Maria Sepúlveda, Sara Llufriu, Yolanda Blanco, Nuria Solà-Valls, Delon La Puma, Joan Berenguer, Pablo Villoslada, Albert Saiz

Published in: Journal of Neurology | Issue 1/2015

Excerpt

Dear Sirs, …

Miravalle A, Jensen R, Kinkel P (2011) Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol 68(2):186–191CrossRefPubMed

Kleinschmidt-DeMasters BK, Miravalle A, Schowinsky J et al (2012) Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab. J Neuropathol Exp Neurol 71(7):604–617CrossRefPubMed

Tan IL, McArthur JC, Clifford DB et al (2011) Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 77(11):1061–1067PubMedCentralCrossRefPubMed

Clifford DB, DeLuca A, Simpson DM et al (2010) Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 9(4):438–446CrossRefPubMed

Salhofer-Polanyi S, Baumgartner A, Kraus J et al (2014) What to expect after natalizumab cessation in a real-life setting. Acta Neurol Scand 130(2):97–102CrossRefPubMed

Lenhard T, Biller A, Mueller W et al (2010) Immune reconstitution inflammatory syndrome after withdrawal of natalizumab? Neurology 75(9):831–833CrossRefPubMed

Daelman L, Maitrot A, Maarouf A et al (2012) Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal. Mult Scler 18(11):1647–1649CrossRefPubMed

Rigau V, Mania A, Béfort P et al (2012) Lethal multiple sclerosis relapse after natalizumab withdrawal. Neurology 79(22):2214–2216CrossRefPubMed

Vennegoor A, Wattjes MP, van Munster ET et al (2011) Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS. Neurology 76(6):574–576CrossRefPubMed

10.

Titulaer MJ, McCracken L, Gabilondo I et al (2013) Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 12(2):157–165PubMedCentralCrossRefPubMed

11.

Borriello G, Prosperini L, Mancinelli C et al (2012) Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study. Eur J Neurol 19:783–787CrossRefPubMed

12.

Capobianco M, di Sapio A, Malentacchi M et al (2014) No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation. Eur J Neurol. doi:10.1111/ene.12487

13.

Havla J, Gerdes LA, Meinl I et al (2011) De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate. J Neurol 258:1665–1669CrossRefPubMed

14.

Havla J, Tackenberg B, Hellwig K et al (2013) Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis. J Neurol 260:1382–1387CrossRefPubMed

15.

Jokubaitis VG, Li V, Kalincik T et al (2014) Fingolimod after natalizumab and the risk of short-term relapse. Neurology 82:1204–1211PubMedCentralCrossRefPubMed

Title: Intense immunosuppression for the treatment of an immune reconstitution inflammatory syndrome-like exacerbation after natalizumab withdrawal: a case report
Authors: Maria Sepúlveda
Sara Llufriu
Yolanda Blanco
Nuria Solà-Valls
Delon La Puma
Joan Berenguer
Pablo Villoslada
Albert Saiz
Publication date: 01-01-2015
Publisher: Springer Berlin Heidelberg
Published in: Journal of Neurology / Issue 1/2015
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-014-7574-6

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Intense immunosuppression for the treatment of an immune reconstitution inflammatory syndrome-like exacerbation after natalizumab withdrawal: a case report

Excerpt

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2015

Ataxia and tremor due to lesions involving cerebellar projection pathways: a DTI tractographic study in six patients

Post-stroke depression and lesion location: a systematic review

Heterogeneous imaging characteristics of JC virus granule cell neuronopathy (GCN): a case series and review of the literature

Erratum to: A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial

Does the vestibular system determine the lateralization of brain functions?

CADASIL in central Italy: a retrospective clinical and genetic study in 229 patients